WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare Conference To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event. Jefferies 2026 Biotech on the Beach Summit About Ardelyx, Inc. Investor and Media Contacts:
Location: Miami, FL
Presentation: Tuesday, March 10 at 4:20 p.m. ET
1×1 Meetings: Tuesday, March 10
Location: Miami, FL
1×1 Meetings: Wednesday, March 11
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA(R) (tenapanor) and XPHOZAH(R) (tenapanor). The company's pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL(R) (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Caitlin Lowie
clowie@ardelyx.com
